mRNA Capabilities

Curia has the expertise and infrastructure to handle RNA therapeutics of up to 20,000 base pairs, supporting the growing demand for complex RNA-based medicines. Recently, Curia successfully conducted process development, scale-up, and cGMP manufacturing for a self-replicating RNA (srRNA) therapy of approximately 10,000 bases. This achievement is particularly significant as srRNA molecules are substantially larger than conventional linear mRNA, presenting unique challenges in synthesis, purification, and large-scale production.

Historically, manufacturing srRNA at the necessary scales for clinical development has been difficult, requiring specialized techniques and process optimizations. Curia’s scientists in Hopkinton, MA, have developed advanced capabilities to overcome these challenges, enabling the efficient production of high-quality RNA therapeutics. Learn more about how our expertise and cutting-edge technologies are driving innovation in mRNA manufacturing.